Global Antibody-drug Conjugates Sales Market Size By Type (Adcetris, Kadcyla), By Application (Breast Cancer, Lymphoma), By Region, And Segment Forecasts, 2023 to 2032

The Global Antibody-drug Conjugates (ADCs) Sales Market was valued at USD 9.8 billion in 2023 and is projected to surpass USD 22.4 billion by 2031, growing at a CAGR of 10.7% during the forecast period 2023-2031.

Antibody-drug conjugates (ADCs) are a class of biopharmaceuticals that combine the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapy drugs. ADCs have emerged as a promising therapeutic option for cancer treatment, offering targeted therapy while minimizing systemic toxicity. The increasing prevalence of cancer, advancements in ADC technology, and growing investments in oncology drug development are driving market expansion.

Drivers

Rising Prevalence of Cancer

The increasing incidence of cancer worldwide is a primary driver for ADC market growth. The World Health Organization (WHO) estimates that cancer cases will rise by 47% between 2020 and 2040, significantly increasing the demand for targeted therapeutics like ADCs.

Advancements in ADC Technology

Technological innovations in linker chemistry, antibody engineering, and payload selection have improved the safety and efficacy of ADCs, making them more effective in treating various cancer types, including breast, lung, and hematological malignancies.

Growing Investment in Oncology Drug Development

Pharmaceutical and biotechnology companies are investing heavily in ADC research, leading to an expanding pipeline of ADCs in clinical trials. Partnerships and acquisitions among key players are further driving market expansion.

Restraints

High Development and Manufacturing Costs

ADCs require complex manufacturing processes, including antibody production, linker synthesis, and cytotoxic drug conjugation, making them expensive to develop and produce. High production costs limit widespread adoption, particularly in developing economies.

Regulatory Challenges

The stringent regulatory approval process for ADCs poses a challenge to market entry. Regulatory agencies like the FDA and EMA require extensive clinical trials and safety evaluations, leading to delays in product launches.

Opportunities

Expansion into Emerging Markets

Pharmaceutical companies are increasingly targeting emerging markets like China, India, and Brazil, where improving healthcare infrastructure and rising disposable income are boosting the adoption of advanced cancer therapies.

Development of Next-generation ADCs

The emergence of next-generation ADCs with improved stability, lower off-target toxicity, and enhanced efficacy presents significant growth opportunities for market players.

Combination Therapies with Immuno-oncology Drugs

The combination of ADCs with immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, is a promising approach that enhances the efficacy of cancer treatment, offering new opportunities for market expansion.

Market by Drug Type Insights

The Kadcyla (T-DM1) segment accounted for the largest market share in 2023 due to its widespread use in treating HER2-positive breast cancer. However, Enhertu (DS-8201) is expected to witness the highest growth rate during the forecast period, driven by its superior efficacy in treating HER2-expressing solid tumors.

Market by End-use Insights

Hospitals dominated the market in 2023, holding over 60% of the market share, owing to the high adoption of ADCs for inpatient oncology treatments.

Specialty Clinics & Cancer Centers are expected to experience the fastest growth due to increasing patient preference for specialized cancer treatment facilities.

Market by Regional Insights

North America:

Held the largest market share in 2023 due to strong R&D investments, presence of leading ADC manufacturers, and increasing adoption of targeted cancer therapies.

Asia-Pacific:

Expected to be the fastest-growing region, driven by rising cancer prevalence, increasing healthcare expenditure, and growing adoption of novel cancer treatments.

Europe:

Significant growth is expected, supported by expanding clinical trials, favorable reimbursement policies, and growing oncology research collaborations.

Competitive Scenario

Key players in the Global ADCs Sales Market include:

Seagen Inc.

Daiichi Sankyo Company, Limited

AstraZeneca plc

Roche Holding AG

Pfizer Inc.

Gilead Sciences, Inc.

ADC Therapeutics

Astellas Pharma Inc.

These companies are focusing on strategic collaborations, clinical trial expansions, and pipeline development to strengthen their market presence. For instance:

In 2023, AstraZeneca and Daiichi Sankyo expanded Enhertu’s approvals to include HER2-mutant non-small cell lung cancer.

In 2024, Seagen partnered with Merck to co-develop novel ADCs for multiple oncology indications.

Scope of Work – Global Antibody-drug Conjugates Sales Market

Key Market Developments

January 2024 – Roche received FDA approval for a new HER2-targeted ADC for breast cancer treatment.

November 2023 – Seagen and Merck expanded their strategic collaboration for the co-development of novel ADCs.

August 2023 – Daiichi Sankyo announced positive Phase III trial results for Enhertu in gastric cancer.

May 2023 – Pfizer acquired ADC Therapeutics, strengthening its oncology pipeline.

FAQs

1. What is the current market size of the Global Antibody-drug Conjugates Sales Market?

The market was valued at USD 9.8 billion in 2023.

2. What is the major growth driver of the Global Antibody-drug Conjugates Sales Market?

The primary growth driver is the rising prevalence of cancer and advancements in ADC technology.

3. Which is the largest region during the forecast period in the Global Antibody-drug Conjugates Sales Market?

North America is expected to remain the largest regional market due to strong R&D investments and the presence of major pharmaceutical players.

4. Which segment accounted for the largest market share in the Global Antibody-drug Conjugates Sales Market?

The Kadcyla (T-DM1) segment accounted for the largest market share in 2023, due to its wide adoption for HER2-positive breast cancer treatment.

5. Who are the key market players in the Global Antibody-drug Conjugates Sales Market?

Leading players include Seagen Inc., Daiichi Sankyo, AstraZeneca, Roche, Pfizer, Gilead Sciences, and ADC Therapeutics.

This report provides a comprehensive, data-driven analysis of the Global Antibody-drug Conjugates Sales Market, offering valuable insights into key market trends, growth drivers, challenges, and opportunities.